FIM
ALNY icon

Freedom Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Freedom Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-934
Closed -$305K – 170
2025
Q2 		$305K Sell
934
-94
-9% -$26K 0.02% 582
2025
Q1 		$278K Sell
1,028
-141
-12% -$36.2K 0.02% 615
2024
Q4 		$275K Buy
1,169
+10
+0.9% +$2.63K 0.02% 625
2024
Q3 		$319K Sell
1,159
-126
-10% -$32.8K 0.03% 578
2024
Q2 		$312K Buy
+1,285
New +$203K 0.03% 579

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Freedom Investment Management's ALNY Position: Q3 2025 in Review

Freedom Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 934 shares — an estimated $305K sold.

Freedom Investment Management first reported a position in ALNY in Q2 2024 and held it in 5 quarters. The position peaked at $319K in Q3 2024. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Freedom Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Freedom Investment Management sold 934 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $305K.
  • Freedom Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Freedom Investment Management's Alnylam Pharmaceuticals position peaked at $319K in Q3 2024.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Freedom Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.